|
Synonyms: AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg
romosozumab is an approved drug (Japan, FDA and EMA (2019))
Compound class:
Antibody
Comment: Romosozumab is a humanised anti-sclerostin monoclonal antibody that was developed by Amgen and UCB for the treatment of osteoporosis [4-5]. Amgen holds patent protection claiming the polypeptide composition of romosozumab in the US and the EU (expected expiry in 2026).
|
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (Japan, FDA and EMA (2019)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 9533 | romosozumab |
| Synonyms |
| AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 404 |
| Other databases | |
| GtoPdb PubChem SID | 249565772 |
| Search PubMed clinical trials | romosozumab |
| Search PubMed titles | romosozumab |
| Search PubMed titles/abstracts | romosozumab |
| Wikipedia | Romosozumab |
